顺尔宁治疗儿童支气管哮喘46例临床分析  

Clinical Analysis of Singulair in Treatment of 46 Cases Bronchial Asthma in Children

作　　者：陈友华 黄俊辉 吴霞 周宇 

机构地区：[1]湖南省湘乡市人民医院儿科,湖南湘乡411400

出　　处：《河北医学》2011年第7期881-883,共3页Hebei Medicine

摘　　要：目的:探讨并总结白三烯受体阻断剂顺尔宁治疗儿童支气管哮喘的临床疗效和应用价值。方法:回顾性分析2006年3月至2009年9月在我院确证为儿童支气管哮喘患儿46例,对照组23例给予常规治疗,观察组23例在常规治疗基础上加用顺尔宁口服。结果:通过比较观察组和对照组治疗后喘息、呼吸困难及哮鸣音消失时间以及对比治疗2周和4周两组症状体征及肺功能缓解情况以及治疗后6个月的复发情况可知,观察组和对照组疗效结果均具有显著性差异(P<0.05)。结论:在常规治疗基础上加用顺尔宁,可使临床缓解时间缩短,预防复发,明显提高患儿生活质量。Objective： To study the clinical effect and application of leukotriene receptor antagonist-Singulair on the bronchial asthma in children. Method： We retrospectively analysed the 46 cases .of children confirmed with asthma in our hospital from 2006.3 to 2009.9. The control group including 23 patients re- ceived conventional therapy, while the 23 cases in observing group received the conventional therapy as well as singulair treatment. Result： The results of observing group and control group were significant different （ P 〈0.05 ） by comparing the disappearance time of wheezing, shortness of breath and wheeze, and the relief of lung function after 2 weeks and d weeks, and the recurrence after 6 months. Conclusion： The conventional treatment as well as singulair can shorten the time of clinical remission and prevent relapse and significantly improve life quality of patients.

关 键 词：儿童支气管哮喘 白三烯受体阻断剂 顺尔宁 

分 类 号：R725.6[医药卫生—儿科]